Skip to main content
Fig. 3 | BMC Medical Genomics

Fig. 3

From: Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma

Fig. 3

a Distribution of predicted mutational signature (MS), which was predominantly presented in each sample. The proportion of samples showing MS-15 (46.6%), MS-6 (13.8%), and MS-18 (8.6%) is presented. b Association between signatures and clinical pathology. The size of each circle represents the number of samples. MS-15 and ganglioneuroblastoma (GNB) histology had a significant association (P value = 0.0012). c Distribution of Tumour Mutation Burden (TMB; n = 58). d Comparison of TMB between high-risk (n = 26) and non-high-risk (n = 32) groups with/without high TMB patients (n = 4). e Correlation between mutational signature weights and TMB. One hyper-mutated sample (TMB > 10) showed MS-18, and three samples with moderate high TMB showed MS-6

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us